Genexine provides immunotherapy and treatments for rare diseases (Image Credits: Genexine official website)

Kindeva Drug Delivery Appoints Jennifer Riter as New VP of Analytical Services

Jennifer-Riter-joins-Kindeva-Drug-Delivery-as-Vice-President-of-Analytical-Services-to-lead-new-analytical-services-business-unit.-Photo-Business-Wire
Jennifer-Riter-joins-Kindeva-Drug-Delivery-as-Vice-President-of-Analytical-Services-to-lead-new-analytical-services-business-unit.-Photo-Business-Wire

Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, recently welcomed Jennifer Riter as Vice President of Analytical Services to head up the recently announced analytical services global business unit.

Riter comes to Kindeva from West Pharmaceutical where she spent the past 27 years in various technical and leadership roles, most recently serving as the Senior Director, Business and Technical Operations. She brings specific leadership and expertise in analytical testing which includes extractables and leachables, container closure integrity and device/combination product performance, and particle analysis. She is the current Chair of the Board of Directors for the Lock Haven University Foundation and teaches a class at University of Maryland Baltimore County as part of the combination products curriculum.

“Kindeva’s expertise in all areas of drug delivery and manufacturing is unmatched in the industry,” Riter said. “I am looking forward to working with the team on expanding our capabilities and expertise in analytical services and working with customers on their analytical approach and strategy for their combination products.”

“Jennifer’s experience blends knowledge of primary packaging components and containment and delivery systems with hands-on experience of providing technical support and analytical solutions to multinational customers,” said Kindeva Global Chief Commercial Officer David Stevens. “The long list of experience and technical knowledge she brings to the team enhances Kindeva as a global drug-device combination CDMO as well as builds the future of integrated and stand-alone analytical support for the wider pharmaceutical, biopharmaceutical, and medical device sector.”

Source

(Visited 94 times, 1 visits today)

Share:

Facebook
Twitter
WhatsApp
LinkedIn

 

Comments are closed.

Social Media

Most Popular

How AI Helps NewbiesVeterans Win at Forex Trading
How AI Helps Newbies/Veterans Win at Forex Trading
7 Ways Technology has Leveraged Retail for Better Customer Experience aaa
7 Ways to Leverage Technology in Retail for Better Customer Experience
Leading waste management infrastructure platform (Image Courtesy: EQT Official website)
EQT and Blackstone Infrastructure to acquire Urbaser,
Instant payouts via Banco (Image Courtesy: Papaya Global Official website)
Papaya Global Launches Global Workforce Wallet Powered by Fireblocks

Related Posts